Estrella Immunopharma Inc (ESLA)

$0.84 +0.00 (0.31%)
Market Cap 30.36M
Revenue (ttm) 0.00
Net Income (ttm) -7.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 31,400
Avg Vol 218,504
Day's Range N/A - N/A
Shares Out 36.17M
Stochastic %K 35%
Beta 0.34
Analysts Strong Sell
Price Target $16.00

Company Profile

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a coll...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 318 9098
Address:
5858 Horton Street, Suite 370, EmeryVille, United States
Hiphipthedip
Hiphipthedip Aug. 6 at 6:12 AM
$ESLA In case one would worry if the recent developments in mRNA support would negatively affect this stock, the answer is: "No." Estrella develops T-Cell immunotherapy targeting leukemia and lymphoma, as well as a technology to mark tumors for target. https://www.theguardian.com/us-news/2025/aug/05/rfk-jr-hhs-mrna-vaccine-research?CMP=Share_AndroidApp_Other
0 · Reply
TheMightySenior
TheMightySenior Aug. 4 at 11:59 PM
$EH. PT $24 $ESLA. PT $16 $ARDX. PT$10 swing trades or hold
0 · Reply
Rasto2020
Rasto2020 Jul. 9 at 5:31 PM
$ESLA I like it
0 · Reply
max315
max315 Jun. 11 at 11:57 AM
$ESLA still holding this snail. But also in at 78c... looking for 1.20-1.30 (private placement is at 1.50/sh) It'll get there. But not one if you need to cash out quick.
0 · Reply
max315
max315 Jun. 5 at 12:43 PM
$ESLA private placement closed at 1.50/share. That's not even dilution, but a private buyer - that's not going to lose $ watching here, over $1
0 · Reply
max315
max315 Jun. 5 at 12:33 PM
$ESLA news: Estrella Immunopharma announces additional site for STARLIGHT-1 trial Estrella Immunopharma announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected Artemis T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
0 · Reply
DonCorleone77
DonCorleone77 Jun. 5 at 12:26 PM
$ESLA Estrella Immunopharma announces additional site for STARLIGHT-1 trial Estrella Immunopharma announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected Artemis T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The new site, Baylor Research Institute d/b/a Baylor Scott & White Research Institute in Dallas, Texas, is now open for patient enrollment.
0 · Reply
CW630
CW630 Jun. 5 at 1:38 AM
$ESLA nice finish
0 · Reply
nlstbro
nlstbro Jun. 4 at 6:06 PM
$ESLA
0 · Reply
whatascam
whatascam Jun. 4 at 12:08 PM
$ESLA Dilution
0 · Reply
Latest News on ESLA
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Jun 5, 2025, 8:00 AM EDT - 2 months ago

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

Jun 3, 2025, 8:00 AM EDT - 2 months ago

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas

May 29, 2025, 8:01 AM EDT - 2 months ago

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

Mar 5, 2025, 8:00 AM EST - 5 months ago

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

Feb 21, 2025, 8:30 AM EST - 5 months ago

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

Feb 19, 2025, 4:46 PM EST - 6 months ago

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

Sep 27, 2024, 12:00 PM EDT - 11 months ago

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

Aug 14, 2024, 12:00 PM EDT - 1 year ago

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

Sep 29, 2023, 10:34 AM EDT - 2 years ago

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

Estrella Immunopharma Nears Completion Of SPAC Listing

Sep 19, 2023, 1:30 AM EDT - 2 years ago

Estrella Immunopharma Nears Completion Of SPAC Listing

TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

Sep 18, 2023, 5:00 PM EDT - 2 years ago

TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.

Oct 3, 2022, 7:27 AM EDT - 3 years ago

Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.

Hiphipthedip
Hiphipthedip Aug. 6 at 6:12 AM
$ESLA In case one would worry if the recent developments in mRNA support would negatively affect this stock, the answer is: "No." Estrella develops T-Cell immunotherapy targeting leukemia and lymphoma, as well as a technology to mark tumors for target. https://www.theguardian.com/us-news/2025/aug/05/rfk-jr-hhs-mrna-vaccine-research?CMP=Share_AndroidApp_Other
0 · Reply
TheMightySenior
TheMightySenior Aug. 4 at 11:59 PM
$EH. PT $24 $ESLA. PT $16 $ARDX. PT$10 swing trades or hold
0 · Reply
Rasto2020
Rasto2020 Jul. 9 at 5:31 PM
$ESLA I like it
0 · Reply
max315
max315 Jun. 11 at 11:57 AM
$ESLA still holding this snail. But also in at 78c... looking for 1.20-1.30 (private placement is at 1.50/sh) It'll get there. But not one if you need to cash out quick.
0 · Reply
max315
max315 Jun. 5 at 12:43 PM
$ESLA private placement closed at 1.50/share. That's not even dilution, but a private buyer - that's not going to lose $ watching here, over $1
0 · Reply
max315
max315 Jun. 5 at 12:33 PM
$ESLA news: Estrella Immunopharma announces additional site for STARLIGHT-1 trial Estrella Immunopharma announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected Artemis T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
0 · Reply
DonCorleone77
DonCorleone77 Jun. 5 at 12:26 PM
$ESLA Estrella Immunopharma announces additional site for STARLIGHT-1 trial Estrella Immunopharma announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected Artemis T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The new site, Baylor Research Institute d/b/a Baylor Scott & White Research Institute in Dallas, Texas, is now open for patient enrollment.
0 · Reply
CW630
CW630 Jun. 5 at 1:38 AM
$ESLA nice finish
0 · Reply
nlstbro
nlstbro Jun. 4 at 6:06 PM
$ESLA
0 · Reply
whatascam
whatascam Jun. 4 at 12:08 PM
$ESLA Dilution
0 · Reply
BetBigWinBigBig
BetBigWinBigBig Jun. 4 at 4:25 AM
$ESLA hate this fk. Bought 1.12 then instantly dropped 30%…
0 · Reply
moneymarker20188
moneymarker20188 Jun. 3 at 9:52 PM
$ESLA buy and hold it
0 · Reply
rolandpuski
rolandpuski Jun. 3 at 7:16 PM
$ESLA 0,82...
1 · Reply
max315
max315 Jun. 3 at 7:10 PM
$ESLA Seriously? what's the deal? private placement at 1.50 and it's going to 70c?
0 · Reply
max315
max315 Jun. 3 at 6:50 PM
$ESLA Now 82c?
0 · Reply
whatascam
whatascam Jun. 3 at 6:38 PM
$ESLA 1 'analyst' and 325 stocktwits followers.
0 · Reply
BetBigWinBigBig
BetBigWinBigBig Jun. 3 at 5:27 PM
$ESLA dont drop please wtf. 🤬
0 · Reply
nlstbro
nlstbro Jun. 3 at 5:21 PM
$ESLA
0 · Reply
Baazigar30
Baazigar30 Jun. 3 at 3:39 PM
$ESLA Congrats; Imo profit taking always part of the game
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Jun. 3 at 3:25 PM
$ESLA I took profits at 1,17
0 · Reply
Baazigar30
Baazigar30 Jun. 3 at 3:22 PM
$ESLA $1.50 Pvt placement with analyst pt $16 buy rating $SONM $20M buy out with another $5M royalties Float only 6M Huge short Over $2 BO price IMO two solid stocks for quick money
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Jun. 3 at 3:16 PM
$ESLA slow and steady $MCTR quick pump =quick dump
2 · Reply